BioSpace News Archive

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas.

Sana Biotechnology, Inc. presented data at the 63rd American Society of Hematology Annual Meeting and Exposition, taking place from Saturday, December 11 to Tuesday, December 14, 2021, which highlighted further progress with key technologies supporting Sana’s in vivo and ex vivo CAR T cell programs.

Protagonist Therapeutics presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera, demonstrating its ability to essentially eliminate the need for phlebotomies in patients.

BeiGene announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia, including the randomized Cohort 1 comparing BRUKINSA to bendamustine plus rituximab and Cohort 3 of BRUKINSA in combination with venetoclax in patients with deletion of chromosome 17p and/or pathogenic TP53 variants.

Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A.

Editas Medicine, Inc., a leading genome editing company, reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell -derived natural killer cell therapies using Editas Medicine’s proprietary AsCas12a gene editing.

Ascentage Pharma announced that the Phase II pivotal study of the company’s novel Bcl-2 selective inhibitor, lisaftoclax, for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has been approved by the Center for Drug Evaluation in China.

Seagen Inc. announced promising efficacy and safety results from Part B of an open-label, phase 2 clinical trial evaluating ADCETRIS® in a novel combination with nivolumab, doxorubicin, and dacarbazine as a frontline treatment for patients with advanced stage classical Hodgkin lymphoma.

Antengene Corporation Limited announced a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor, Opdivo®.

IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.